

moconiosis consisting predominantly of MDF-type nodules with or without silicotic nodule or massive fibrosis. Classic silicosis is meant in cases where almost all lesions are silicotic nodule. Silicosis and mixed dust pneumoconiosis are distinct entities clinicopathologically (18). Massive fibrosis, active tuberculosis and alveolar proteinosis are more common in cases with silicosis. Mixed dust pneumoconiosis tends to be associated with DIE more frequently.

References

- Nagelschmidt G. *The relation between lung dust and lung pathology in pneumoconiosis*. Br J Med 1960; 17: 247-259.
- Craighead JE, Kleinerman J, Abraham JL et al. *Diseases associated with exposure to silica and nonfibrous silicate minerals*. Arch Pathol Lab Med 1988; 112: 673-720.
- Honma K, Chiyotani K. *Pulmonary alveolar proteinosis as a component of massive fibrosis in cases of chronic pneumoconiosis. An autopsy study of 79 cases*. Zentralbl Pathol 1991; 137: 414-417.
- Green EHY, Churg A. *Diseases due to nonasbestos silicates*. In: Churg A, Green FHY (Eds.). *Pathology of Occupational Lung Disease*. Igaku-Shoin, New York/Tokyo 1988; 177-211.
- Honma K, Chiyotani K. *Diffuse interstitial fibrosis in nonasbestos pneumoconiosis - A pathological study* Respiration 1993; 60: 120-126.
- Roggli VL. *Asbestos bodies and nonasbestos ferruginous bodies*. In: Roggli VL, Greenberg AD, Pratt PC (Eds.). *Pathology of Asbestos-Associated Diseases*. Little, Brown and Company, Boston/Toronto/London 1992; 39-75.
- Green FHY, Churg A. *Pathologic features of occupational lung disease*. In: Churg A, Green FHY (Eds.). *Pathology of Occupational Lung Disease*. 2nd ed. Williams & Wilkins, Baltimore 1998; 21-44.
- Chariot P, Monnet I, De Cramous H et al. *Protibino alvolaire at exposition professionnelle*. Ann Med Interne 1991; 142: 197-202.
- Morgan WKC. *Bronchitis, airways obstruction and occupation*. In: Parkas WR (Ed.). *Occupational Lung Disorders*. 3rd ed. Butterworth-Heinemann, Oxford 1994; 238-252.
- Hustan K. *Die Steinstauberkrankungen der Ruhrbergleute*. Klin Wochenschr 1931; 10: 506-508.
- Honma K, Taguchi O, Chiyotani K et al. *Pathogenetic relationship between tuberculosis and pneumoconiotic massive fibrosis - an autopsy survey*. In: Chiyotani K, Hosoda Y, Aizama Y (Eds.). *Advances in the Prevention at Occupational Respiratory Diseases*. Elsevier, Amsterdam 1998; 819-824.
- Ziskind M, Jones RN, Waill H. *Silicosis*. Am Rev Respir Dis 1976; 113: 643-665.
- Caplan A. *Certain unusual radiological appearances in the chest of coal miners suffering from rheumatoid arthritis*. Thorax 1953; 8: 29-37.
- Gough J, Rivers O, Seal RME. *Pathological studies of modified pneumoconiosis in coal miners with rheumatoid arthritis (Caplan's syndrome)*. Thorax 1955; 10: 9-18.
- International Agency for Research on Cancer World Health Organization: *ARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. Silica, some Silicates, Coal Dust and Para-aramid Fibres*. 1997; 68.
- Honma K, Chiyotani K, Kimura K. *Silicosis, mixed dust pneumoconiosis, and lung cancer* Am J Ind Med 1997; 32: 595-599.
- Vallyathan V, Green EHY, Rodman NE et al. *Lung carcinoma by histologic type in coal miners*. Arch Pathol Lab Med 1985; 109: 419-423.
- Honma K. *Nonasbestos pneumoconiosis nowadays*. Jpn J Traumatol Occup Med 1996; 44: 452-456.

tors which are related to occurrence and prognosis are still missing. Similar to investigations in lung cancer, the analysis of basic structure elements in combination with the involved inflammatory cell types seems to be appropriate for the characterization of chronic interstitial lung diseases. Therefore, transbronchial lung biopsies taken from patients with chronic interstitial lung diseases were incubated with the following antibodies: CD3, CD20, macrophage migration inhibitory factor (MIF), galectin-1, galectin-3, galectin-8, CD-34; and the biotinylated substances galectin-1, galectin-3, sarcolectin, and carrier-immobilized cortisone. Cases with various of the following rare interstitial lung diseases were analyzed in relation to the HR-CT findings: sarcoidosis, usual interstitial pneumonia, lymphoid interstitial pneumonia, pulmonary hemosiderosis, carbohydrate deficiency syndrome, systemic lupus erythematoses, pulmonary ossification, alveolar proteinosis, bronchiolitis obliterans, acute and chronic eosinophilic pneumonia, and inflammatory lung reaction due to various cytostatic drug regimes. The expression of binding capacities was measured by use of a semiautomated image analyzing system, and the spatial relation of the binding and nonbinding cells was calculated. The amount of fibrosis was measured by use of Sirius-red stain.

As a result, the expression of the analyzed determinants differs not only in the percentage of specific cells but also in the spatial arrangement. For example, the alveolar spaces of alveolar proteinosis are characterized by rare populations of B-cells and macrophages (and absence of macrophage migration inhibitory factor). Missing presence and binding capacities of MIF were, in addition, noted in sarcoidosis and cytostatic drug reactions. Vascularization was disturbed in cases with usual interstitial pneumonia (UIP) and lymphocytic interstitial pneumonia (LIP), whereas in cases with eosinophilic pneumonia the vascular arrangement was notably preserved. These investigations are derived from similar measurements of structure features and entropy of primary and metastatic lung tumors (1-3), and confirm the practical use of the analysis of tissue structures. In addition, the expression of binding capacities of immobilized sugar-binding substances (lectins) and their antibodies can be used to determine specific interactions of involved inflammatory cells in altered lung parenchyma due to various agents (4-6). Thus, modern image analyzing techniques in combination with immuno- and ligand histochemistry permit detailed insight into the arrangement of various cellular subpopulations and the underlying interstitial and vascular matrix. The response of the idiopathic lung diseases to corticosteroids is related to the amount of irreversible fibrosis (collagen IV) and the expression of binding capacities of cortisone. The spatial arrangement of the different cell types and cells with the different functional states seems to be of importance for the outcome of the various diseases.

References

- Kayser K, Gabius HJ. *Graph theory and the entropy concept in histochemistry. Theoretical considerations, application in histopathology and the combination with receptor-specific approaches*. Progr Histochem Cytochem 1997; 32(2): 1-106.
- Kaysar K, Gabius HJ. *How to apply thermodynamic principles to histochemical and morphometric tissue research - principles and practical outline with focus on glycosciences*. Cell Tissue Res (in press).
- Kaysar K, Hagemayer O. *Stage related morphometry of sarcoid granulomas and inflammatory cell types in broncho-alveolar lavage*. ACP J 1991; 3: 335-342.
- Kaysar K, Gabius HJ, Probst F et al. *Are there characteristic alterations of lung tissue associated with Crohn's disease? Path Res Pract 1990; 186: 485-490.*
- Kayser K, Zeilinger C, Zang FY et al. *Detection of the lymphokine migration inhibitory factor in normal and disease-affected lung by antibody and by its major binding protein, the interferon antagonist sarcolectin*. Path Res Pract 1993; 189: 992-995.

Perspectives of cellular sociology in chronic interstitial lung diseases

K. Kayser¹, S. Zink¹, E. Hauck¹, V. Schulz²
and H.-J. Gabius³

¹Dept. of Pathology ²Dept. of Pulmonology Thoraxklinik, Heidelberg,
³Institute of Physiological Chemistry University of Munich, Munich.

The development and outcome of chronic interstitial lung diseases is still subject of intensive scientific investigations. In particular, fac-

6. Kaysar K, Bovin NV, Wiegandt H et al. *Labelled neoglycoconjugates: Neoglycoproteins and other biotinylated carriers of bioactive ligands in morphological diagnosis.* Arq Patol 1994; 26: 19-26.

Etiology, pathogenesis and differential diagnosis of lung granulomatosis. An update

H.H. Popper

Laboratory of Environmental and Respiratory Pathology, Institute of Pathology University of Graz, Graz, Austria.

Slowly dissolving or even insoluble particles or organisms generally cause the formation of granulomas in the lung as elsewhere in the body. These might enter the lung by inhalation or by circulation via blood vessels. Living organisms or organic and inorganic particulate matter might cause granuloma formation. This can both be driven and regulated by immune mechanisms or by the older phylogenetic mechanism of phagocytosis and lysosomal degradation, with few or no participating lymphocytes.

The granuloma is defined as a nodular, well-circumscribed inflammatory lesion composed of either histiocytes (histiocytic granuloma), epithelioid and giant cells (epithelioid cell or sarcoid granuloma), Langerhans' cells (Langerhans' cell granulomatosis, histiocytosis X), foreign body giant cells (foreign body granuloma), or fibroblasts with hyalinization (hyalinizing granuloma), respectively. These granulomas can have an additional mixture of neutrophils, eosinophils, or lymphocytes. Additional structural features might be encountered, such as vasculitis or necrosis.

Formation of granulomas by immune mechanisms can either progress along a T-helper 1-lymphocyte profile, ruled and regulated by cytokines such as tumor necrosis factor- α (TNF- α), interleukin (IL)-3, IL-12, interferon- γ (IFN- γ), or by a T-helper 2-lymphocyte profile and the respective cytokines IL-4, and IL-5, or even by a T-cytotoxic-suppressor-lymphocyte profile, for which predominant cytokines are not well known.

Granulomas might develop central necrosis by many different mechanisms, such as thrombosis or vasculitis, followed by infarct-like necrosis. Mediator induced platelet aggregation and coagulative necrosis, by apoptosis, or by perforins released by natural killer cells.

The differential diagnosis of granulomatosis starts at the cellular level, by first differentiating the granulomas by their predominant cell types into the forms found below.

Epithelioid cell granulomatosis are further divided into necrotizing and non-necrotizing. From this point special techniques are required to define the causing agent. By acid fast stains or polymerase chain reaction (PCR), mycobacteria are proven, while silver impregnation or immunohistochemical stains are necessary to define fungi, and other special stains are necessary to prove various parasitic infections. If living organisms are excluded, autoimmune or allergic diseases have to be considered. The former can be proven by additional features, such as necrosis and granulocytic vasculitis in Wegeners granulomatosis, or by additional palisading histiocytic granulomas, necrosis and disruption of collagen as in rheumatoid arthritis. Additional lymphocytic bronchitis, bron-

chiolitis and lymphocytic interstitial infiltrates with or without follicles characterize the latter, as in exogenous allergic alveolitis (EAA). Non-necrotizing sarcoid granulomas with or without granulomatous vasculitis are seen in sarcoidosis/necrotizing sarcoid granulomatosis! nodular sarcoidosis-complex, as well as in chronic allergic metal disease. Eosinophilic or neutrophilic bronchiolitis is a characteristic feature in bronchocentric granulomatosis/allergic bronchopulmonary mycosis. Indistinguishable from sarcoidosis, epithelioid cell reaction in tumor draining lymphatics requires clinical information or an additional biopsy showing the causative tumor.

Histiocytic granulomatosis can be induced by inorganic dust, such as silicium oxides and silicates, coal dust, toner dust, etc. The causing mineral can be proven by polarized light microscopy, EDAX analysis or laser mass spectrophotometry (LAMA). The immune system in immunocompromised patients might not be able to exhibit a sarcoid reaction and therefore histiocytic granulomas or even loose aggregates of histiocytes and macrophages are formed. This implies that in histiocytic granulomatosis without visible dust particles, special stains have to be performed to rule out infection. Often *Mycobacterium* other than tuberculosis complex, such as *M. leprae* in endemic areas, are the causing agents. A combination of histiocytic and epithelioid cell granulomas is seen in lungs affected by rheumatoid arthritis and in bronchocentric granulomatosis. The former contain destroyed collagen, while the latter shows remnants of fungi and eosinophilia (allergic variant) or microorganisms and neutrophilia (infectious variant).

If particles, either inhaled or recirculated to the lungs, cannot be easily dissolved by the first line of defense (i.e., the macrophages), the host forms foreign body granulomas. Although some cytokines, such as IL-1 β , which are secreted by macrophages and probably also by a few bypassing lymphocytes, are necessary for giant cell formation by fusion and/or nuclear division, with the process of granuloma formation not being regarded as immunologic. Phylogenetically, this mechanism can already be found in primitive multicellular organisms. A wide variety of inhaled materials can be found and are most often food. Material entering the lungs through the blood stream can be shedded particles from dialysis membranes or other medical devices, and inorganic chemicals like talcum in drug abusers.

Foreign body granulomas are also seen in different forms of pulmonary amyloidosis and in the very early phases of some pneumoconiosis (silicosis, asbestosis, and hard metal lung disease). Pulmonary microlithiasis is a very rare disease causing foreign body granulomatosis. In this condition, many large and small alveoloths can be found, surrounded by foreign body giant cells, sometimes forming granulomas. Some of the alveoloths may be free in the alveoli, but most of them are within the alveolar walls.

The characteristic features of hyalinizing granulomas are their sharp delineation and their acellular centers. Usually a dense lymphocytic and plasmocytic infiltration is seen at the rim of the hyalinized nodules, but also within the nodule. Most patients are either children or patients in their second decade of life. The typical features of collagen fibers can be seen under polarized light.

References

- Binford H, Dooley JR. *Deep fi4ycoses.* In: Binford CH, Connor DH (Eds.). Pathology of Tropical and Extraordinary Diseases. Armed Forces Institute of Pathology, Washington, DC, 1976; 565ff.
- Chensue SW, Warrington K, Ruth JH et al. *Effect of slow release IL-12 and IL-10 on inflammation, local macrophage function and the regional lymphoid response during mycobacterial (Th1) and schistosomal (Th2) antigen-elicited pulmonary granuloma formation.* Int J Inflamm 1997; 46: 86-92.